Dr
Orano Med LLC
Author in the following contributions
- 212Pb-NNV003 as a novel targeted alpha therapy for CD37 positive B-cell chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL)
- Targeted alpha-emitter therapy of neuroendocrine tumors using 212Pb-octreotate (AlphaMedix TM)
- Investigating the potential of 212Pb-rituximab as an alpha-radioimmunotherapy for the treatment of Non-Hodgkin’s Lymphoma